Listed

Ernexa Therapeutics Inc.: Form 10-K for the period ended Dec 31, 2020

Filed with the SEC on Mar 11, 2021 and accepted by EDGAR at Mar 11, 2021, 17:07 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2020-01-01 to 2020-12-31$5.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development12 months2020-01-01 to 2020-12-31$2.0kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2020-01-01 to 2020-12-31$8.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2020-01-01 to 2020-12-31−$6.3mus-gaap:OperatingIncomeLoss
Income tax12 months2020-01-01 to 2020-12-31−$6.0kus-gaap:IncomeTaxExpenseBenefit
Net income12 months2020-01-01 to 2020-12-31−$4.4mus-gaap:NetIncomeLoss
Operating cash flow12 months2020-01-01 to 2020-12-31−$3.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2020-12-31$777.0kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-12-31$1.7mus-gaap:AssetsCurrent
Total assetsAt period end2020-12-31$3.7mus-gaap:Assets
Current liabilitiesAt period end2020-12-31$2.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-12-31$2.9mus-gaap:Liabilities
Long-term debtAt period end2020-12-31$532.0kus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2020-12-31$1.5mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2020-12-31$851.0kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-21-005827. Last ingested by Listed: Nov 11, 2026, 02:49 ET. Listed shows no prices and gives no investment advice.